PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 254 filers reported holding PACIRA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.88 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,101,748 | -22.6% | 101,100 | +1.1% | 0.00% | -33.3% |
| Q2 2023 | $4,007,000 | -0.8% | 100,000 | +1.0% | 0.00% | 0.0% |
| Q1 2023 | $4,040,190 | -5.4% | 99,000 | -10.5% | 0.00% | 0.0% |
| Q4 2022 | $4,270,266 | -25.5% | 110,600 | +2.7% | 0.00% | -25.0% |
| Q3 2022 | $5,729,000 | -6.7% | 107,700 | +2.3% | 0.00% | 0.0% |
| Q2 2022 | $6,139,000 | -23.6% | 105,300 | 0.0% | 0.00% | -20.0% |
| Q1 2022 | $8,036,000 | +36.6% | 105,300 | +7.7% | 0.01% | +25.0% |
| Q4 2021 | $5,885,000 | +8.1% | 97,800 | +0.6% | 0.00% | +33.3% |
| Q3 2021 | $5,443,000 | -6.4% | 97,200 | +1.5% | 0.00% | -25.0% |
| Q2 2021 | $5,813,000 | -12.0% | 95,800 | +1.6% | 0.00% | 0.0% |
| Q1 2021 | $6,609,000 | +20.3% | 94,300 | +2.7% | 0.00% | 0.0% |
| Q4 2020 | $5,493,000 | +0.7% | 91,800 | +1.2% | 0.00% | 0.0% |
| Q3 2020 | $5,453,000 | +16.6% | 90,700 | +1.8% | 0.00% | 0.0% |
| Q2 2020 | $4,675,000 | +91.5% | 89,100 | +22.4% | 0.00% | +33.3% |
| Q1 2020 | $2,441,000 | -24.8% | 72,800 | +1.5% | 0.00% | 0.0% |
| Q4 2019 | $3,248,000 | +22.1% | 71,700 | +2.6% | 0.00% | 0.0% |
| Q3 2019 | $2,661,000 | -11.2% | 69,900 | +1.5% | 0.00% | 0.0% |
| Q2 2019 | $2,996,000 | +5.1% | 68,900 | -8.0% | 0.00% | 0.0% |
| Q1 2019 | $2,851,000 | -8.5% | 74,900 | +3.5% | 0.00% | -25.0% |
| Q4 2018 | $3,115,000 | -9.2% | 72,400 | +3.7% | 0.00% | 0.0% |
| Q3 2018 | $3,431,000 | +53.4% | 69,800 | 0.0% | 0.00% | +33.3% |
| Q2 2018 | $2,237,000 | +2.9% | 69,800 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $2,174,000 | -31.8% | 69,800 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $3,186,000 | +26.4% | 69,800 | +4.0% | 0.00% | 0.0% |
| Q3 2017 | $2,520,000 | -16.3% | 67,100 | +6.3% | 0.00% | -25.0% |
| Q2 2017 | $3,010,000 | +7.7% | 63,100 | +2.9% | 0.00% | +33.3% |
| Q1 2017 | $2,795,000 | +44.7% | 61,300 | +2.5% | 0.00% | 0.0% |
| Q4 2016 | $1,932,000 | -5.6% | 59,800 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $2,046,000 | -2.0% | 59,800 | -3.4% | 0.00% | 0.0% |
| Q2 2016 | $2,088,000 | -33.2% | 61,900 | +1.3% | 0.00% | -50.0% |
| Q1 2016 | $3,126,000 | -13.6% | 61,100 | +29.7% | 0.01% | -33.3% |
| Q4 2015 | $3,617,000 | +86.8% | 47,100 | 0.0% | 0.01% | +80.0% |
| Q3 2015 | $1,936,000 | -32.9% | 47,100 | +15.4% | 0.01% | -28.6% |
| Q2 2015 | $2,885,000 | -15.2% | 40,800 | +6.5% | 0.01% | -22.2% |
| Q1 2015 | $3,403,000 | +1.6% | 38,300 | +1.3% | 0.01% | -30.8% |
| Q4 2014 | $3,351,000 | -6.1% | 37,800 | +2.7% | 0.01% | -7.1% |
| Q3 2014 | $3,567,000 | +13.5% | 36,800 | +7.6% | 0.01% | +16.7% |
| Q2 2014 | $3,142,000 | +43.4% | 34,200 | +9.3% | 0.01% | +33.3% |
| Q1 2014 | $2,191,000 | +59.5% | 31,300 | +31.0% | 0.01% | +80.0% |
| Q4 2013 | $1,374,000 | +19.6% | 23,900 | 0.0% | 0.01% | 0.0% |
| Q3 2013 | $1,149,000 | +58.5% | 23,900 | -4.4% | 0.01% | +66.7% |
| Q2 2013 | $725,000 | – | 25,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |